---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116489"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T00:40:09.989213+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cyclacel Q3: net loss $5.1M, cash $23.7M; oral fadraciclib shows 2 partial responses in T-cell lymphoma

## Summary
- Cash $23.7M at Sept 30, 2022 (vs $36.6M at Dec 31, 2021); cash runway expected to fund programs to end of 2023.
- Oral fadraciclib Phase 1/2: 18 evaluable patients; 2/3 partial responses in T-cell lymphoma, 11 stable diseases across solid tumors.
- Oral CYC140 Phase 1/2: no DLTs; durable stable disease at first dose level in ovarian and KRAS G12V NSCLC patients.
- Terminating sapacitabine license with Daiichi Sankyo, effective March 23, 2023; not pursuing further development.
- Expect to determine RP2D for fadraciclib in 4Q 2022 and start Phase 2 in 1H 2023.

## SEC filing metadata
- accession: 0001104659-22-116489
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/0001104659-22-116489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/tm2230005d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116489
- JSON: https://secwatch.observer/filing/0001104659-22-116489.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116489.txt

## Key facts
- Earnings Releases
  Bio Green Med Solution, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “ Company ”), dated November 9, 2022, announcing certain financial results for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1130166/000110465922116489/0001104659-22-116489-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.